Flu vaccine no longer mandated for U.S. troops, defense secretary says American service members are free to get the shot but will not be forced to

https://www.statnews.com/2026/04/21/flu-vaccine-military-no-longer-required-hegseth/ By Associated PressApril 21, 2026

BioAge says experimental pill aimed at reducing heart risks significantly reduced inflammation The company, like others, is betting reduced inflammation can lead to better health outcomes

https://www.statnews.com/2026/04/21/bioage-drug-inflammation-cardiovascular-risks/ By Elaine ChenApril 21, 2026 Elaine Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech.

In early trial, CAR-T results raise hope of preventing multiple myeloma in high-risk patients Experts at AACR applaud study but debate when this aggressive approach would be suitable

https://www.statnews.com/2026/04/20/aacr-2026-car-t-trial-results-carvykti-smoldering-multiple-myeloma/ By Angus ChenApril 20, 2026 Cancer Reporter

Morning Briefing: Today's News Summaries Tuesday, Apr 21 2026 UPDATED 9:47 AM

Morning Briefing: Today's News Summaries Tuesday, Apr 21 2026 UPDATED 9:47 AM https://kffhealthnews.org/morning-briefing/tuesday-april-21-2026/ To Better Prevent Cyberattacks, FBI Asks Hospitals To Step Up Info-Sharing https://kffhealthnews.org/morning-breakout/to-better-prevent-cyberattacks-fbi-asks-hospitals-to-step-up-info-sharing/ Autism Risk Linked To Common Drugs Taken During Pregnancy, Study Finds https://kffhealthnews.org/morning-breakout/autism-risk-linked-to-common-drugs-taken-during-pregnancy-study-finds/ Diets High In Fruits, Veggies May Raise Risk Of Lung Cancer In Younger People; Exposure To Pesticides Questioned https://kffhealthnews.org/morning-breakout/diets-high-in-fruits-veggies-may-raise-risk-of-lung-cancer-in-younger-people-exposure-to-pesticides-questioned/ Constitutionality Of Abortion Upheld In Pa.; Medicaid Fund Use Ban Is Lifted https://kffhealthnews.org/morning-breakout/constitutionality-of-abortion-upheld-in-pa-medicaid-fund-use-ban-is-lifted/ Supreme Court Rejects Lawsuit Over Covid-Era Nursing Home Policy In NY https://kffhealthnews.org/morning-breakout/supreme-court-rejects-lawsuit-over-covid-era-nursing-home-policy-in-ny/ High Court Rebuffs Gender Transition Case But OKs Case On Religious Rights https://kffhealthnews.org/morning-breakout/high-court-rebuffs-gender-transition-case-but-oks-case-on-religious-rights/

New mechanism disables antibiotic resistance and cross-protection in bacteria

https://www.news-medical.net/news/20260421/New-mechanism-disables-antibiotic-resistance-and-cross-protection-in-bacteria.aspx A newly discovered mechanism renders antibiotic-resistant bacteria vulnerable by disabling both their individual resistance and a process known as cross-protection, the ability of resistant bacteria to shield nearby, otherwise sensitive strains. This occurs because resistant bacteria can degrade antibiotics in their surroundings, reducing drug levels and allowing other microbes to survive. By targeting this shared defense, researchers aim to restore the effectiveness of antibiotics, enabling them to eliminate not only resistant bacteria but also the susceptible microbes they protect.

Greater control over test ordering choices is top of mind for patients

https://www.linkedin.com/pulse/greater-control-over-test-ordering-choices-top-mind-icbff/ As the consumerization of healthcare rises, patients are thinking more like paying customers with expectations that reflect a familiar adage: The customer is always right. Survey data reveals what people in the U.S. expect from lab and “DIY”-testing – and why interest is set to grow in parallel with increased healthcare costs, and longevity and wellness goals. In this issue, Michele Zwickl, head of Laboratory Solutions for Diagnostics, Siemens Healthineers North America, talks us through: the study’s findings major challenges facing clinicians and lab professionals as DIY testing expands what we might expect as AI tools expand to help interpret health data

Targeting HRD and BRCA: The Expanding Role of PARP Inhibitors in Ovarian Cancer Treatment by CheckRare Staff| Published on: Feb 20, 2026

Targeting HRD and BRCA: The Expanding Role of PARP Inhibitors in Ovarian Cancer Treatment by CheckRare Staff| Published on: Feb 20, 2026 PRIMA Clinical Trial Bradley J. Monk, MD, Medical Director, Florida Cancer Specialists and Research Institute, West Palm Beach, and Founder of GOG Partners, discusses the clinical advances in the treatment of ovarian cancer, including research using PARP inhibitors, which can change standard of care for women with certain tumor types. https://checkrare.com/parp-inhibitors-in-ovarian-cancer-treatment/

Phase 3 Results of Brepocitinib for the Treatment of Dermatomyositis by Madaline Spencer| Published on: Apr 21, 2026

Phase 3 Results of Brepocitinib for the Treatment of Dermatomyositis by Madaline Spencer| Published on: Apr 21, 2026 Ben Zimmer, CEO of Priovant Therapeutics, discusses results from the recent phase 3 study testing brepocitinib for the treatment of dermatomyositis (DM). https://checkrare.com/phase-3-results-of-brepocitinib-for-the-treatment-of-dermatomyositis/

An opportunity to confront multimorbidity The Lancet Public Health ++... +

An opportunity to confront multimorbidity The Lancet Public Health https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00078-2/fulltext?dgcid=raven_jbs_etoc_email Issue cover for Volume 11, Issue 5 May 2026 Volume 11Number 5e268-e348 https://www.thelancet.com/journals/lanpub/issue/vol11no5/PIIS2468-2667(26)X2004-7 Effect of the online Rethink My Drink alcohol intervention on alcohol use and cognition in older adults in Australia: a randomised controlled trial Louise Mewton, PhDa Send email to louise.mewton@sydney.edu.au ∙ Virginia Winter, MClinNeuroa ∙ Nicholas Hoy, PhDa ∙ Rachel Visontay, PhDa ∙ Sarah Davies, MBMScb,c ∙ Nicole Kochan, PhDd ∙ et al. https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00056-3/fulltext?dgcid=raven_jbs_etoc_feature_lanpub

Editorial From burden to leadership: renewing the fight against malaria in Africa The Lancet Regional Health – Africa +++ +...

The Masanga Fever Study (MaFeStu): a prospective hospital-based observational study of causes of febrile illness in rural Sierra Leone Laura C. Kalkmana,b ∙ Emmanuel M. Kanua,b ∙ Emmanuel B. Bachea,b ∙ Ika Septihandayania,b ∙ Emil Kellinga,b ∙ Islam M. Kargboa ∙ et al. https://www.thelancet.com/journals/lanafr/article/PIIS3050-5011(26)00006-4/fulltext?dgcid=hubspot_update_feature_updatealerts_lanafr&utm_campaign=42584649-update-lanafr&utm_medium=email&_hsenc=p2ANqtz--rtXovexZowR1OqSe2Yb-bCR7yiXFO0WbvJUtw-RawssWb018VEU1GGh9s1zJIz7qzzrBlry8cXj5iyJWDes0dWekNNA&_hsmi=414739635&utm_content=414355605&utm_source=hs_email Virologic outcomes among people living with HIV on dolutegravir-based antiretroviral therapy in Kenya, 2018–2024: a comparison retrospective longitudinal analysis Helen M Chuna Send email to vgi2@cdc.gov ∙ Sherri L. Palsa ∙ Mary Gikurad ∙ Pacific Akinyie ∙ Ashley Odhiambod ∙ Emilio Dirlikovc ∙ et al. https://www.thelancet.com/journals/lanafr/article/PIIS3050-5011(26)00009-X/fulltext?dgcid=hubspot_update_feature_updatealerts_lanafr&utm_campaign=42584649-update-lanafr&utm_medium=email&_hsenc=p2ANqtz-9C88beEJdpYkcU1q6IuUTHR5nwposcTJPmYrYbQZQdJb0K0llIg2MEOxm651Ia_HxJGa0B2DTFGhQFs3_5xyHQeVXUZw&_hsmi=414739635&utm_content=414355605&utm_source=hs_email Urbanisation, lifestyle, and sleep health in West Africa: the Benin Society and Sleep (BeSAS) cross-sectional study Ablo Prudence Wachinoua,b,c,g Send email to wachinouprudence@yahoo.fr ∙ Pervenche Mefo Fotsob ∙ Salmane Amidouc ∙ Arnauld Fiogbeb ∙ Serge Aded ∙ Corinne Houéhanoue ∙ et al. https://www.thelancet.com/journals/lanafr/article/PIIS3050-5011(26)00018-0/fulltext?dgcid=hubspot_update_feature_updatealerts_lanafr&utm_campaign=42584649-update-lanafr&utm_medium=email&_hsenc=p2ANqtz-9PcCnlRcFLm3HyTKYPKLthgNtQuYzfmOHKUer6jSPLbccoJer5265omHEZRk2uWsYn9g6mRNqVs61SCVFMQ1gw29PeeQ&_hsmi=414739635&utm_content=414355605&utm_source=hs_email Editorial From burden to leadership: renewing the fight against malaria in Africa The Lancet Regional Health – Africa https://www.thelancet.com/journals/lanafr/issue/vol2nonull/PIIS3050-5011(26)X2002-8

Editorial When recommendations meet reality: the challenge of walking in the Americas The Lancet Regional Health – Americas ++... ++

The neglected role of partner treatment in congenital syphilis control in Brazil: nationwide evidence from 2007 to 2023 Mariana D. Fernandesa,b,g ∙ Rodrigo C. Menezesa,b,c,g ∙ Isadora B.C. Almeidaa,b ∙ Catarina D. Fernandesb,d ∙ Isabella B.B. Ferreiraa,b ∙ Bruno B. Andrade https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00064-5/fulltext?dgcid=hubspot_update_feature_updatealerts_lanam&utm_campaign=update-lanam&utm_medium=email&_hsenc=p2ANqtz-_Pxt5be_QUkv1zDr5poA8fMtbGFo3YusYPmLw38v9rwCZ22AbleMUa4yCDT2JWXzEeJYxQHs23gbbP2eZDdmpiHgbR5Q&_hsmi=414570749&utm_content=414103068&utm_source=hs_email Editorial When recommendations meet reality: the challenge of walking in the Americas The Lancet Regional Health – Americas https://www.thelancet.com/journals/lanam/issue/vol56nonull/PIIS2667-193X(26)X2001-4 Renal cell carcinoma incidence and mortality in California: a population-based study of sociodemographic patterns and temporal trends from 1988 through 2019 Kevin L'Espérancea,b Send email to klesp@stanford.edu ∙ Katherine Linc ∙ Daphne Lichtensztajnc ∙ Simon John Christoph Soerensena,b ∙ Shuchi Gulatid ∙ Zhengyi Denga,b ∙ et al. https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00060-8/fulltext?dgcid=hubspot_update_feature_updatealerts_lanam&utm_campaign=update-lanam&utm_medium=email&_hsenc=p2ANqtz--H8Ax236geLUgVsfN39GfEA_G-WohigY0DdIMcytilAsISz2wMJM_4XLtwcU9iGseDzWl0gS4nh7Nz1CLKlu4eiFJpVA&_hsmi=414570749&utm_content=414103068&utm_source=hs_email Early-onset colorectal cancer in Argentina: a multicenter surgical analysis of incidence, stage, and metastatic patterns Juan Pablo Campanaa ∙ Tomas Cifonea ∙ Esteban Gonzalez Salazara ∙ Gustavo Rossia ∙ Ricardo Mentza ∙ Carlos Vaccaroa ∙ et al. https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00045-1/fulltext?dgcid=hubspot_update_feature_updatealerts_lanam&utm_campaign=update-lanam&utm_medium=email&_hsenc=p2ANqtz--5QgBfnJoXUuaWU3dcKtGYVe38VzhO-U4ptDkC3D2Edztu_6l0Ch4q0G9hZFxyaXar0_5oTGATvYKf_VQGLlEmA6AvVg&_hsmi=414570749&utm_content=414103068&utm_source=hs_email

Precision Oncology in HER2-Mutated NSCLC: Strategies for Today and Tomorrow Authors: Yong Fang, MD; Hye Ryun Kim, MD, PhD; Hibiki Udagawa, MD, PhD

https://www.medscape.org/viewarticle/precision-oncology-her2-mutated-nsclc-strategies-today-and-2025a100105r?page=1&src=mkmcmr_driv_stan_mscpedu_260420-OUS-HONC-precision-oncology-her2-mutated-nsclc-strategies-today-and-2025a100105r-cta&uac=148436CN

Highlights From the Annual Neuro-Oncology Conference: Redefining IDH-Mutant Glioma Management Authors: Evanthia Galanis, MD; Shawn Hervey-Jumper, MD; Katherine B. Peters, MD, PhD, FAAN; Matthias Preusser, MD

https://www.medscape.org/viewarticle/1003198?uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260420-OUS-HONC-1003198-cta

Advancing Personalized Care for Prostate Cancer: Patient-Centered Solutions for mHSPC and nmCRPC Authors: Alicia K. Morgans, MD, MPH, FASCO; Christian Gratzke, MD; Fred Saad, MD, FRCS, FCAHS; Tony Collier, BE

https://www.medscape.org/viewarticle/advancing-personalized-care-prostate-cancer-patient-centered-2025a1000uyb?page=1&src=mkmcmr_driv_stan_mscpedu_260421-OUS-HONC-advancing-personalized-care-prostate-cancer-patient-centered-2025a1000uyb-cta&uac=148436CN

Locally Advanced Rectal Cancer Responds to HER2 Therapy Will Pass April 21, 2026 +++ +++

Locally Advanced Rectal Cancer Responds to HER2 Therapy Will Pass https://www.medscape.com/viewarticle/locally-advanced-rectal-cancer-responds-her2-therapy-2026a1000chn April 21, 2026 American Association for Cancer Research (AACR) Annual Meeting 2026 https://www.medscape.com/c25/p14/american-association-cancer-research-aacr-annual-meeting-2026a10009yj NICE Backs New Oral Second-Line Option for CLL Dr Sheena Meredith https://www.medscape.com/viewarticle/nice-backs-new-oral-option-second-line-cll-2026a1000chv Medscape UK April 21, 2026 Can Oncotype DX Predict Recurrence Risk in Older Patients With Breast Cancer? Edited by Victoria Stern https://www.medscape.com/viewarticle/can-oncotype-dx-predict-recurrence-risk-older-patients-2026a1000cfd April 21, 2026 AI Holds Promise in Dermatology, Issues Remain to be Addressed Damian McNamara, MA https://www.medscape.com/viewarticle/ai-holds-promise-dermatology-issues-remain-be-addressed-2026a1000cik April 21, 2026 Should Aspirin Be Reconsidered for Colon Cancer Prevention? Cristina Ferrario https://www.medscape.com/viewarticle/should-aspirin-be-reconsidered-colon-cancer-prevention-2026a1000cge April 21, 2026

Mixed Tuberculous and Aspergillus Empyema in a Man Céline Fey April 21, 2026

https://www.medscape.com/viewarticle/mixed-tuberculous-and-aspergillus-empyema-man-2026a1000cgd

Optimizing the Transplant Experience: A Patient Journey Through Conditioning and GvHD Management Authors: Daniele Avenoso, MD, PhD; Filippo Milano, MD, PhD; Mareike Verbeek, MD; Robert Zeiser, MD

https://www.medscape.org/viewarticle/optimizing-transplant-experience-patient-journey-through-2026a1000bh8?page=1

Highlights From San Francisco: The Evolving Role of The Radiation Oncologist in Lower-Grade Glioma Care Authors: Erik P. Sulman, MD, PhD; Mitchel S. Berger, MD; Benjamin M. Ellingson, PhD; Lia M. Halasz, MD; Michael Weller, MD

https://www.medscape.org/viewarticle/1003169?src=mkmcmr_driv_stan_mscpedu_260421-OUS-HONC-1003169-cta&uac=148436CN

Expert-Driven, Patient-Focused: Mastering Personalized Care for HER2-Low Metastatic Breast Cancer Authors: Kevin Kalinsky, MD, MS, FASCO

https://www.medscape.org/viewarticle/1002880?src=mkmcmr_driv_stan_mscpedu_260420-OUS-HONC-1002880-cta&uac=148436CN

FDA Grand Rounds: FDA Grand Rounds presented by the Office of Women’s Health: FDA Menopausal Hormone Therapy (MHT) Labeling: Historical Context and Recent Changes

FDA Grand Rounds presented by the Office of Women’s Health: FDA Menopausal Hormone Therapy (MHT) Labeling: Historical Context and Recent Changes Thursday, April 23, 2026 12:00 p.m. - 1:00 p.m. ET Webcast CME Credit Offered https://www.fda.gov/science-research/about-science-research-fda/fda-grand-rounds?utm_medium=email&utm_source=govdelivery About the Presentation: Join FDA’s Office of Women’s Health (OWH) and the Center for Drug Evaluation and Research (CDER) for an FDA Grand Rounds Webcast on Menopausal Hormone Therapy (MHT). This lecture will provide the historical and regulatory context of MHT which led to the creation of the Women's Health Initiative studies, as well as the results of those studies and the subsequent impact. The lecture will also describe the rationale for the FDA’s requests to update the MHT labeling and describe the labeling changes in each of the 4 MHT product categories.

Cell therapy primed liver transplant patients to avoid organ rejection, small study shows Getting live liver donor’s cells pre-surgery may teach recipient’s body to see organ as friend not foe

https://www.statnews.com/2026/04/17/organ-transplant-new-approach-immunosuppression-nature-communications-study/ By Elizabeth CooneyApril 17, 2026 Cardiovascular Disease Reporter

A pancreatic cancer expert on why Revolution Medicines’ study could ‘open up a new era’ of treatment An investigator in a trial of daraxonrasib believes it could open the floodgates for better therapies

https://www.statnews.com/2026/04/17/revolution-medicines-daraxonrasib-clinical-trial-readout-loud-podcast-transcript/ By Adam Feuerstein, Allison DeAngelis, and Elaine ChenApril 17, 2026

Eating fruits, vegetables and whole grains may increase chance of early onset lung cancer

https://news.keckmedicine.org/eating-fruits-vegetables-and-whole-grains-may-increase-chance-of-early-onset-lung-cancer/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-8nmsNYPQKJXVAWu9gIMrx535tdrnvkNA8YXGuEfmi6-QM41i3b2uIrY-O8RYow6TkdhyQzQxCi92iPGEbvXdjmi7EQkQ&_hsmi=414424977&utm_content=414424977&utm_source=hs_email A controversial cancer study abstract comes to AACR I had to read the headline twice when I saw the press release: "Eating fruits, vegetables and whole grains may increase the chance of early onset lung cancer," according to new research from the USC Norris Comprehensive Cancer Center that will be presented tomorrow at the annual American Association for Cancer Research meeting. The claim comes from a survey study of 187 patients who were diagnosed with lung cancer by age 50, most of whom had never smoked. The authors speculated that pesticides might be a contributing factor. But outside experts eviscerated the research methods. Peter Shields, a medical oncologist at Ohio State University, noted in a statement that experts have long known leanness to be a risk factor for lung cancer, which could explain the authors’ findings. “This is only a conference abstract, but the flaws of the study and its conclusions are quite striking,” Baptiste Leurent, a medical statistics professor at University College London said in a comment. “Jumping to the conclusion that [healthier eating] could cause lung cancer is quite a stretch, let alone implicating pesticides.” There’s a few days of the conference left. For the latest, strongest reporting on what’s going on there, sign up for STAT’s AACR in 30 Seconds newsletter. And don't miss his special report on KRAS inhibitors from yesterday. https://www.statnews.com/2026/04/19/daraxonrasib-pancreatic-cancer-kras-revolution-medicines-patient-story/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-_n6zjIRrEVNHBUPx8XywMTa_m2bywaG3kQR2RKaIb3tTUaEsd0kgHgDUSq6Jw3GHzxxS3IgBB95MVpepXSvF6OrdKKLg&_hsmi=414424977&utm_content=414424977&utm_source=hs_email

AI is turning the healthcare revenue cycle into an operating system

https://www.statnews.com/sponsor/2026/03/30/ai-is-turning-the-healthcare-revenue-cycle-into-an-operating-system/ While clinical uses of artificial intelligence (AI) grab headlines, the fast-growing technology’s first big, measurable win in healthcare is already happening within the revenue cycle. The key question now facing healthcare organizations is how best to prioritize the needs and interests of various stakeholders, including administrators, clinical staff, patients and payers, when deploying AI. While healthcare providers that invest their revenue cycle AI dollars in isolated point solutions may see incremental gains in processes and workflows, they come at the cost of adding a new layer of fragmentation to an already disjointed structure — disconnected tools, inconsistent logic, duplicated review and more workflow handoffs. A comprehensive, system-level approach treating the revenue cycle as an end-to-end operating model, on the other hand, delivers compounding returns — stronger financial performance, improved staff retention and a better patient experience.

Measles outbreak means my immunocompromised son can’t leave the house without extreme safety measures As measles spreads in my state, my community has forgotten the lessons of Covid

https://www.statnews.com/2026/04/20/immunocompromised-children-measles-return-mmr-community/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-88gXtYV4pGKf82-tQzdUKNJqPROeHwCayomySpCYTbmC2CkeIAaGxi29GHZIzVionKGEmygMNVVWSJwWSFtdWGFG73zA&_hsmi=414424977&utm_content=414424977&utm_source=hs_email By Penelope GatlinApril 20, 2026 Gatlin is a rare disease parent, advocate, and member of the Parent Advisory Board of the CSNK2A1 Foundation. The safety measures one family must take amid a measles outbreak Since 2020, Penelope Gatlin and her family have completely changed their lives to protect her 13-year-old son’s health. He has Okur-Chung neurodevelopment syndrome, an ultra-rare genetic disorder that can lead to autism, intellectual disabilities, low muscle tone, and more. Gatlin forgoes work travel and in-person meetings, and her husband has left the workforce completely. They still wear masks and social distance outside. Now, they have another infectious disease to worry about. The family lives in North Carolina, one of 32 states facing a measles outbreak. “The resurgence of measles is a threat to the health of every child, but for immunocompromised kids like mine, it is catastrophic,” she writes. Read more about how the family is grappling with skepticism among friends — and even health care professionals — who say their fear of measles is overblown.

Adolescent Cannabis Use After Cannabis Legalization and the COVID-19 Pandemic

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2847868?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz--LDKKRNWBTzWEfOx8-3Are9wO5lKYA47VGVW85WIJjRAiTselrOtwzOu7nTvD3Cw1mNBThKixqdNcqTO0MHB_2hgz8nA&_hsmi=414424977&utm_content=414424977&utm_source=hs_email How weed affects adolescent brains In a study of more than 11,000 kids and teens, those who use cannabis showed slower progression over time when it came to memory, attention, language, and cognitive processing speed. The difference was small at times, the researchers acknowledge, but could still be significant. Often, those who used cannabis displayed a cognitive advantage at early ages, only to be surpassed by those in the control group as they aged. The research, published yesterday in Neuropsychopharmacology, used data from the NIH-supported Adolescent Brain Cognitive Development Study, following youth from around age nine through 17. Cannabis use was self-reported and confirmed with biological testing from hair, urine, and saliva samples. Relatedly, another study published Friday in JAMA Network Open found that rates of adolescent cannabis use increased after recreational use was legalized in California, but decreased after the Covid pandemic. https://www.nature.com/articles/s41386-026-02395-1

The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades By Angus ChenApril 19, 2026

The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades Long pursuit of common mutation appears to be paying off for patients and for Revolution Medicines https://www.statnews.com/2026/04/19/daraxonrasib-pancreatic-cancer-kras-revolution-medicines-patient-story/ By Angus ChenApril 19, 2026

RARE Revolution RARE Bite

https://editions.rarerevolutionmagazine.com/html5/reader/production/default.aspx?pubname=&edid=cfec555e-0bf6-4813-9494-6b9538dbfd94&pnum=3 In a world where ‘make memories’ is a key mainstay of clinical advice the stakes cannot be higher. This unbearable weight is a toll few on the outside can ever truly understand. There is therefore, something else that sits at the centre of all this—love. Love in its many forms. A father’s love—promises made, and unimaginable final acts of love. A mother’s love— being the glue, surviving ‘life after’, and everything inbetween. Lovers, love—couples torn apart and trying to find their way back to each other. So, with spring in the air, this edition, supported by Azafaros, is dedicated simply to those who love—love at any cost—love that sees this community continue to give, even when their love is lost. All for the benefit of others and the greater good for families of the future, families they may never know. And to the pioneers who dedicate their careers to keeping love, and hope alive in all its forms.

The rise of the agentic AI colleague The Lancet Digital Health ++... ++

The rise of the agentic AI colleague The Lancet Digital Health https://www.thelancet.com/journals/landig/article/PIIS2589-7500(26)00033-6/fulltext?dgcid=raven_jbs_etoc_email Mar 2026 Volume 8Number 3 https://www.thelancet.com/journals/landig/issue/vol8no3/PIIS2589-7500(26)X2003-9 A predictive atlas of disease onset from retinal fundus photographs: a modelling study using data from population-based cohorts Thore Buergel, PhDa,b,∗ ∙ Lukas Loock, MSca,∗ ∙ Jakob Steinfeldt, MDb,c,d,e,∗ ∙ Noel Kronenberg, BSca ∙ Laura Hoffmann, MDk ∙ Steffen Emil Künzel, MDk ∙ et al. https://www.thelancet.com/journals/landig/article/PIIS2589-7500(25)00144-X/fulltext?dgcid=raven_jbs_etoc_feature_landig Artificial intelligence-based pathological model for pan-cancer lymph node metastasis detection: a multicentre diagnostic study with retrospective and prospective validation Shaoxu Wu, MDa,∗ ∙ Guibin Hong, MDa,∗ ∙ Yun Wang, MDa,∗ ∙ Hong Zeng, MDb,∗ ∙ Zhen Lin, MEc,∗ ∙ Jie Yang, MDd,∗ ∙ et al. https://www.thelancet.com/journals/landig/article/PIIS2589-7500(25)00143-8/fulltext?dgcid=raven_jbs_etoc_feature_landig

CLINICAL PERSPECTIVE + + + + + + + (videos)

CLINICAL PERSPECTIVE Investigational Dual AAV Gene Therapy for Patients With Stargardt Disease https://checkrare.com/investigational-dual-aav-gene-therapy-for-patients-with-stargardt-disease/ Miquel Vila-Perello, PhD, co-founder and CEO of SpliceBio, discusses an investigational dual adeno-associated virus (AAV) gene therapy in development for patients with Stargardt disease. Psychological Aspects of Rare Autoimmune and Ophthalmic Diseases https://checkrare.com/psychological-aspects-of-rare-autoimmune-and-ophthalmic-diseases/ A study published in World Journal of Clinical Cases investigated the psychological aspects of rare autoimmune and ophthalmic diseases, such as mental well-being and everyday functioning. Rapid Eye Movement Sleep Behaviour Disorder in Moebius Syndrome https://checkrare.com/rapid-eye-movement-sleep-behaviour-disorder-in-moebius-syndrome/ A study published in The Cureus Journal of Medical Science analyzed a case study of an adolescent with Rapid Eye Movement (REM) sleep behaviour disorder in Moebius syndrome. FDA’s Plausible Mechanism Framework and its Effect on Rare Disease Therapy Development https://checkrare.com/fdas-plausible-mechanism-framework-and-its-effect-on-rare-disease-therapy-development/ Stevie Ringel, CEO of Nome Therapeutics, discusses the US Food and Drug Administration’s (FDA) Plausible Mechanism Framework and its effect on rare disease therapy development. Phase 2 Results of Dusquetide in the Treatment of Oral Ulcers Caused by Behçet’s Disease https://checkrare.com/phase-2-results-of-dusquetide-in-the-treatment-of-oral-ulcers-caused-by-behcets-disease/ Results from a phase 2a study evaluating SGX945 (dusquetide) for the treatment of Behçet’s disease were published in Rheumatology (Oxford). Advancing Thyroid Eye Disease Care: Integrating Tepezza, New Technology, and Optimizing Multidisciplinary Teams https://checkrare.com/advancing-thyroid-eye-disease-care-integrating-tepezza-new-technology-and-optimizing-multidisciplinary-teams/ Maja Kostic, MD, PhD, Assistant Professor of Ophthalmology at the University of North Carolina at Chapel Hill, discusses advancements in thyroid eye disease (TED) care. Results from the TEASE-2 Clinical Trial of Gildeuretinol in Patients With Stargardt Disease https://checkrare.com/results-from-the-tease-2-clinical-trial-of-gildeuretinol-in-patients-with-stargardt-disease/ Philip J. Ferrone, MD, Vitreoretinal Consultants of New York, discusses results from the TEASE-2 clinical trial of gildeuretinol in patients with Stargardt disease.

Biomarkers and Beyond: Integrating AI in Rare Disease Management (Full Program)

Tepezza (Teprotumumab) for the Treatment of Thyroid Eye Disease by Madaline Spencer| Published on: Apr 20, 2026

Tepezza (Teprotumumab) for the Treatment of Thyroid Eye Disease by Madaline Spencer| Published on: Apr 20, 2026 Prem Subramanian, MD, PhD, Chief of Neuro-Ophthalmology at the University of Colorado Anschutz, discusses Tepezza (teprotumumab-trbw) for the treatment of thyroid eye disease (TED). https://checkrare.com/tepezza-teprotumumab-for-the-treatment-of-thyroid-eye-disease/

Europe at a brain health crossroads The Lancet Neurology ++... + +

Europe at a brain health crossroads The Lancet Neurology https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00132-8/fulltext?dgcid=raven_jbs_etoc_email May 2026 Volume 25Number 5p433-532, e11 https://www.thelancet.com/journals/laneur/issue/vol25no5/PIIS1474-4422(26)X2003-8 Hot Brain 4: climate change and neurological disorders: mechanisms By UCL Queen Square Institute of Neurology Kennedy Lecture Theatre, Institute of Child HealthLondon, England Tuesday 12 May • 9 - 17 https://www.eventbrite.co.uk/e/hot-brain-4-climate-change-and-neurological-disorders-mechanisms-tickets-1980871259260 Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 GBD 2023 Meningitis & Antimicrobial Resistance Collaborators https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00101-8/abstract?dgcid=raven_jbs_etoc_feature_laneur

Beyond PSMA: Preparing Your Practice for the Next Wave of Prostate Cancer Biomarkers Authors: Karim Fizazi, MD, PhD; Bertrand Tombal, MD, PhD; Alberto Briganti, MD, PhD

https://www.medscape.org/viewarticle/beyond-psma-preparing-your-practice-next-wave-prostate-2026a10006ql?page=1&src=mkmcmr_driv_stan_mscpedu_260419-OUS-HONC-beyond-psma-preparing-your-practice-next-wave-prostate-2026a10006ql-cta&uac=148436CN

Challenges and Opportunities for CAR T-Cell Therapies to Treat Autoimmune Rheumatic Diseases Authors: Eric Morand, MD, PhD; David Simon, MHBA; Fabian Müller, MD; Gerhard Krönke, MD, MHBA

https://www.medscape.org/viewarticle/1003043?uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260419-OUS-HONC-1003043-cta

Navigating Cytopenias in Myelofibrosis: Tailoring Personalized Care for Optimal Outcomes Authors: Francesca Palandri, MD; Vikas Gupta, MD, FRCPath; Jennifer O'Sullivan, MD

https://www.medscape.org/viewarticle/navigating-cytopenias-myelofibrosis-tailoring-personalized-2026a10004km?page=1&src=mkmcmr_driv_stan_mscpedu_260419-OUS-HONC-navigating-cytopenias-myelofibrosis-tailoring-personalized-2026a10004km-cta&uac=148436CN

Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer 2026

https://www.medscape.com/c25/p14/society-gynecologic-oncology-sgo-annual-meeting-womens-2026a10009hl

What Precedes Aid With Dying in Young Adults With Cancer? Edited by Gargi Mukherjee April 20, 2026 +++++

https://www.medscape.com/viewarticle/what-precedes-aid-dying-young-adults-cancer-2026a1000cbq In a retrospective cohort study of 34 adolescent and young adult patients with cancer who received medical assistance in dying (MAID) in Alberta, Canada, symptom burden increased sharply about 5 months before death, yet only half received specialist palliative care within 3 months of death. Patients experienced high symptom complexity, particularly tiredness, poor well-being, and pain, and 80% cited the loss of ability to engage in meaningful activities as the primary source of suffering. Vitamin C’s Potential Use in Cancer Is Getting a Second Look Alice McCarthy https://www.medscape.com/viewarticle/vitamin-cs-potential-use-cancer-getting-second-look-2026a1000ca3 April 20, 2026 When Garry Buettner, PhD, who has been studying the chemistry and biochemistry of vitamin C for at least four decades, was diagnosed with myelodysplastic syndromes (MDS), he applied his research to his own life — reviewing the data and designing a protocol for his treatment. Immunotherapy Combo Shows Promise for Hodgkin Lymphoma Edited by Gargi Mukherjee https://www.medscape.com/viewarticle/immunotherapy-combo-shows-promise-hodgkin-lymphoma-2026a1000c8x April 20, 2026 Brentuximab vedotin and nivolumab combined with doxorubicin and dacarbazine (AN+AD) was associated with a high complete response rate and encouraging short-term progression‑free survival (PFS) in patients with nonbulky early-stage classical Hodgkin lymphoma (cHL), according to a recent phase 2 study. Any‑grade treatment‑emergent adverse events occurred in almost all patients, and peripheral sensory neuropathy was common, but most cases were low-grade and resolved or improved, and no cases of febrile neutropenia were reported. Osimertinib Maintains Quality of Life in Patients With Stage III EGFR-Mutated NSCLC After Chemoradiotherapy Edited by Vineeta Teotia https://www.medscape.com/viewarticle/osimertinib-maintains-quality-life-patients-stage-iii-egfr-2026a1000byu Osimertinib maintained health-related quality of life (QOL) and functioning in patients with unresectable stage III epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after definitive chemoradiotherapy, with no clinically meaningful deterioration in patient-reported outcome (PRO) scores. Is Vitamin D a Key to Better Breast Cancer Survival? Ernie Mundell https://www.medscape.com/viewarticle/vitamin-d-key-better-breast-cancer-survival-2026a1000c9y April 20, 2026 For women with breast cancer, vitamin D levels around the time of diagnosis might be related to long-term survival, a large prospective study showed.

Right to Try: Promise vs Reality in Cancer Care Charlotte Huff April 17, 2026

https://www.medscape.com/viewarticle/right-try-promise-vs-reality-cancer-care-2026a1000c17 Several years ago, Anita Turk, MD, assistant professor of clinical medicine at the Indiana University School of Medicine in Indianapolis, was treating a patient with advanced gastrointestinal cancer. The woman was in a dire situation: She faced a life-threatening diagnosis and had no FDA-approved treatment options or clinical trial opportunities.

HER2-Positive Early Breast Cancer: What the Latest Data Mean for Your Practice Authors: Judy King, MRCP, PhD; Charles Geyer, MD

https://www.medscape.org/viewarticle/her2-positive-early-breast-cancer-what-latest-data-mean-your-2026a10002fg?page=1&src=mkmcmr_driv_stan_mscpedu_260420-OUS-HONC-her2-positive-early-breast-cancer-what-latest-data-mean-your-2026a10002fg-cta&uac=148436CN

Best practices in cardiometabolic trial design: Planning and optimization for success

https://www.news-medical.net/whitepaper/20260417/Best-practices-in-cardiometabolic-trial-design-Planning-and-optimization-for-success.aspx Cardiometabolic disease is not a singular entity. Obesity, ectopic fat deposition, insulin resistance, and chronic inflammation are among the common causes of this diverse group of illnesses. It includes diabetes, cardiovascular disease, fatty liver disease, heart failure, and even certain malignancies. Each condition provides unique obstacles, although they are linked by overlapping pathophysiology. This complication makes cardiometabolic research both scientifically appealing and operationally hard. Designing and optimizing trials in this sector necessitates meticulous planning, adaptability, and a thorough understanding of endpoints, recruitment realities, and regulatory expectations.

Redesigning obesity trials for a chronic disease era

https://www.news-medical.net/whitepaper/20260417/Redesigning-obesity-trials-for-a-chronic-disease-era.aspx For much of its history, obesity research has struggled to find a place in clinical development. Too medical to dismiss outright, too entangled with lifestyle narratives to command the same seriousness as closely related conditions such as cardiovascular disease or diabetes. It has frequently been studied through a narrow lens – short trials, blunt endpoints, and the underlying assumption that weight loss was the only outcome that mattered.

How Soil Bacteria Could Help Solve Antibiotic Resistance

https://www.news-medical.net/health/How-Soil-Bacteria-Could-Help-Solve-Antibiotic-Resistance.aspx Beneath our feet lies a hidden pharmaceutical frontier: soil microbes are yielding new antibiotic leads just as scientists race to outpace the global rise of antimicrobial resistance. Antimicrobial resistance (AMR) is one of the most serious threats to modern medicine, with recent reviews citing roughly 4.95 million deaths associated with antibacterial resistance globally in 2019.1,3

What Are the Best Alternatives to Opioids for Chronic Pain Relief

https://www.news-medical.net/health/What-Are-the-Best-Alternatives-to-Opioids-for-Chronic-Pain-Relief.aspx From first-in-class sodium channel inhibitors to inflammation-targeted and digital interventions, this article shows how pain science is reshaping chronic pain treatment beyond opioids. Recent advances in pain science, including the development of sodium channel-inhibiting drugs and a more thorough understanding of nociplastic pain, are expanding the landscape of non-opioid treatment options. Chronic pain is now increasingly understood as a multifactorial condition involving dysregulated nociceptive processing, central sensitization, and neuroimmune interactions, rather than only tissue damage. This article explores the mechanisms and physiological advantages of these emerging pain management strategies.

What Causes Hair Loss in Women? Hormones, Aging, and Genetics Explained

https://www.news-medical.net/health/What-Causes-Hair-Loss-in-Women-Hormones-Aging-and-Genetics-Explained.aspx From adolescent hormone signaling to menopausal follicular decline, this article reveals how life-stage biology shapes the patterns, causes, and clinical nuances of hair loss in women. This article discusses the biological causes of hair loss in women, focusing on the hair growth cycle, follicle structure, and the roles of hormones such as estrogen and androgens in regulating hair growth and shedding. Hair loss in women is multifactorial, involving genetic predisposition, endocrine influences, environmental triggers, and systemic health conditions that vary across the lifespan.2,3

Editorial The risks of AI-generated health advice eClinicalMedicine ++...

Development of an early prediction model for endometriosis risk: the simplified adolescent factors for endometriosis (SAFE) score Gita D. Mishraa g.mishra@uq.edu.au ∙ Mohammad Reza Baneshia ∙ Sally Mortlocka ∙ Grant W. Montgomeryb ∙ Jenny Dousta ∙ Annette J. Dobsona ∙ et al. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00053-2/fulltext?dgcid=hubspot_email_infocusalerts-obgyn_feature&utm_campaign=infocusalerts-obgyn&utm_medium=email&_hsenc=p2ANqtz-8dBVpAiuYGq7LXWmh0Gvb3d9_Qzhsa5ISaWD1cSa90c5PcymuusnVK92l8B1ekxSmX4E5YYmZpKp1kiNsCOUplQZLsJQ&_hsmi=414375122&utm_content=413879779&utm_source=hs_email Editorial The risks of AI-generated health advice eClinicalMedicine https://www.thelancet.com/journals/eclinm/issue/vol93nonull/PIIS2589-5370(26)X2002-8

Editorial Reimagining radiology reporting The Lancet Digital Health ++...

End-to-end integrative segmentation and radiomics prognostic models for risk stratification of high-grade serous ovarian cancer: a retrospective multicohort study Kristofer Linton-Reid, PhDa,b ∙ Haonan Lu, PhDa,b,c ∙ Georg Wengert, MDa,b,d,f ∙ Prof Christina Fotopoulou, MDa ∙ Philippa Lee, MDd ∙ Federica Petta, MDe ∙ et al. https://www.thelancet.com/journals/landig/article/PIIS2589-7500(25)00137-2/fulltext?dgcid=hubspot_email_infocusalerts-obgyn_feature&utm_campaign=infocusalerts-obgyn&utm_medium=email&_hsenc=p2ANqtz-8vFfb7SjaOKj5L65xULIYY74UepEvf_Ae_ShhehUegdzFmvRGbJ5Ekg7u46b_BxaJ0Hrmp3twbMeODojwYi0g4nAshtA&_hsmi=414375122&utm_content=413879779&utm_source=hs_email Editorial Reimagining radiology reporting The Lancet Digital Health https://www.thelancet.com/journals/landig/issue/vol8no2/PIIS2589-7500(26)X2002-7

Humanity first, not country first The Lancet Regional Health – Europe + +... ++ +...

The effectiveness of psychosocial interventions for self-harm in males compared to females: a systematic review and meta-analysis Oliver Matias Oliver.Matias@citystgeorges.ac.uk ∙ Alexandra E. Bakou ∙ Kirsten Barnicot ∙ Rose McCabe https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00018-9/fulltext?dgcid=hubspot_update_feature_updatealerts_lanepe&utm_campaign=update-lanepe&utm_medium=email&_hsenc=p2ANqtz-_6QghD46vbVyE0L1AwSpldCO9iYyG-U0C7iKQk0oYrtVqrUuzCAC1_93ylRZN_kH_fimm7B5n0xzl2HiMz8tgC4ifdRw&_hsmi=413587672&utm_content=413506161&utm_source=hs_email Cutting-edge systemic cancer therapies Executive summary Systemic cancer therapies are undergoing rapid transformation, redefining precision and durability in oncologic treatment. This Series examines advances across antibody–drug conjugates, cell therapies, multispecific antibodies, and immunologically driven strategies such as oncolytic viruses and cancer vaccines. It highlights how innovations in molecular design, conjugation technologies, and antibody engineering are expanding therapeutic potential while introducing challenges related to toxicity, cost, and access. The Series also explores the growing role of engineered cell therapies in haematological malignancies and solid tumours, emphasising Europe’s scientific leadership alongside regulatory and manufacturing barriers. Advances in immune engagement underscore a shift toward more precise and durable antitumour responses, while reinforcing the need for biomarker-guided patient selection and system-level solutions to translate innovation into equitable clinical benefit. https://www.thelancet.com/series-do/cancer-therapies?dgcid=hubspot_update_feature_lanepecancertherapies26&utm_campaign=update-lanepe&utm_medium=email&_hsenc=p2ANqtz-9Iv30TOsv86ubzEPvvi7y09sDdaNoJxYby5gKpAJq_uAuz1hIvQpGLf2MgjAH0enHrK161StJw5_-if2okpprLT1f70g&_hsmi=413587672&utm_content=413506161&utm_source=hs_email European medicines agency approvals of new medicines in January and February 2026 Bruno Sepodesa,b ∙ Juan Garcia Burgosc ∙ Steffen Thirstrup https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00069-4/fulltext?dgcid=hubspot_update_feature_updatealerts_lanepe&utm_campaign=update-lanepe&utm_medium=email&_hsenc=p2ANqtz-9THJdPjb1atX04h2d9CGSxtNbidbKL6AHPyZO5Y7ErBrwLtOtjg9HCH8GafIDDrff_OPsoB5FAJ1yYWiF6U4RKGcIKkg&_hsmi=413587672&utm_content=413506161&utm_source=hs_email Humanity first, not country first The Lancet Regional Health – Europe https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00076-1/fulltext?dgcid=hubspot_update_feature_updatealerts_lanepe&utm_campaign=update-lanepe&utm_medium=email&_hsenc=p2ANqtz--v2vIxd72bJVaEkaNOXJ2X-9-cCUsdGPGZ3hn_zSKQL11EW4Lj7f0AxQnBKQ9qjNNIutT1d9ZcxapW9d9H0Zl_YrbV7A&_hsmi=413587672&utm_content=413506161&utm_source=hs_email Apr 2026 Volume 63 https://www.thelancet.com/journals/lanepe/issue/vol63nonull/PIIS2666-7762(25)X0014-4

CLINICAL PERSPECTIVES +++ (3 videos)

CLINICAL PERSPECTIVES New Clinical Trial Testing On-Demand Use of Deucrictibant in Patients With Hereditary Angioedema https://checkrare.com/new-clinical-trial-testing-on-demand-use-of-deucrictibant-in-patients-with-hereditary-angioedema/ Peng Lu, MD, PhD, Chief Medical Officer at Pharvaris, and Wim Souverijns, PhD, Chief Commercial Officer at Pharvaris, discuss the RAPIDe-3 clinical trial of deucrictibant for patients with hereditary angioedema (HAE). ASMD Perspective Index: Diagnosing Niemann-Pick Disease https://checkrare.com/asmd-perspective-index-diagnosing-niemann-pick-disease/ John Taggart, Head of Communications at Niemann-Pick UK (NPUK), discusses the ASMD Perspective Index and its use in diagnosing Niemann-Pick disease. New Formulation of Berotralstat for Treatment of Pediatric Patients With Hereditary Angioedema https://checkrare.com/new-formulation-of-berotralstat-for-treatment-of-pediatric-patients-with-hereditary-angioedema/ Raffi Tachdjian, MD, Associate Clinical Professor of Medicine & Pediatrics, Division of Allergy & Clinical Immunology, University of California Los Angeles, discusses a new formulation of Orladeyo (berotralstat) for the treatment of pediatric patients with hereditary angioedema (HAE).

Biomarkers and Beyond: Integrating AI in Rare Disease Management by CheckRare Staff| Updated on: Apr 18, 2026

https://checkrare.com/biomarkers-and-beyond-integrating-ai-in-rare-disease-management/ Stacey Kallish, MD, Clinical Geneticist at Penn Medicine in Philadelphia, is helping to lead a new wave of innovation at the intersection of artificial intelligence (AI) and rare disease care. With a clinical focus on lysosomal storage diseases (LSDs)—including Fabry disease, Gaucher disease, and Pompe disease—Dr. Kallish is exploring how emerging technologies can improve diagnosis, risk prediction, and long-term management for patients with complex genetic conditions.

First-Gen College: Breaking Barriers, Beating The Odds By Ivanhoe Broadcast News on April 20, 2026

Orlando, Fla. (Ivanhoe Newswire) — When you’re the first in your family to earn a college degree, it’s a major milestone, not just for you, but for generations to come. According to the National Center for Education Statistics, one-third of all college students in the United States are first-generation. And while the achievement is historic, the transition can be tough. https://www.ivanhoe.com/?p=36946&preview=1&_ppp=29610927b9

Digital Dangers: Crime Without Contact By Ivanhoe Broadcast News on April 21, 2026

Orlando, Fla. (Ivanhoe Newswire) — Digital dangers aren’t just annoying; they’re costing Americans billions. Latest numbers reveal cyber criminals stole more than 16 billion dollars last year, nearly 6.5 million people reported fraud or identity theft, that’s about one victim every five seconds. And more than half of adults say they’ve been targeted by a scam through email, text or phone. https://www.ivanhoe.com/?p=36948&preview=1&_ppp=517edf6f9d

Earning Above Poverty Line But Still Feeling Broke? By Ivanhoe Broadcast News on April 22, 2026

Orlando, Fla. (Ivanhoe Newswire) — Talks of recession, high prices, and layoffs have left many Americans on edge. But here’s what may surprise you, financial stress is hitting people who aren’t even considered “poor.” https://www.ivanhoe.com/?p=36951&preview=1&_ppp=fb9cee1683

From Avocados To E-Bikes: ER Docs Sound The Alarm! By Ivanhoe Broadcast News on April 23, 2026

Orlando, Fla. (Ivanhoe Newswire) — More than 155 million Americans visit the emergency room each year and doctors say many of those trips are preventable. So what everyday habits are sending people to the ER? And what simple changes could keep you out? https://www.ivanhoe.com/?p=36954&preview=1&_ppp=8641f7a95c

Spring Allergies: Earlier, Longer, Stronger By Ivanhoe Broadcast News on April 24, 2026

Orlando, Fla. (Ivanhoe Newswire) — One in three adults and one in three kids deal with seasonal allergies each year. Spring allergies are lasting longer and hitting harder than in years past. Experts say it’s not just pollen. Warmer temperatures and higher carbon dioxide levels are giving plants a head start on blooming and producing more pollen than before. That means more days of itchy eyes, sneezing, and coughs for millions of Americans. https://www.ivanhoe.com/?p=36957&preview=1&_ppp=b84e2cc95f

Steps for Personalized and Collaborative Decision-Making in HER2-Mutated NSCLC Authors: Pasi Jänne, MD, PhD, FASCO; Soo-Ryum (Stewart) Yang, MD; Xiuning Le, MD, PhD

https://www.medscape.org/viewarticle/steps-personalized-and-collaborative-decision-making-her2-2026a10007ur?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260418-OUS-HONC-steps-personalized-and-collaborative-decision-making-her2-2026a10007ur-cta

Navigating Myelofibrosis-Associated Anemia Together: Empowering Collaboration and Communication Authors: Francesco Passamonti, MD

https://www.medscape.org/viewarticle/navigating-myelofibrosis-associated-anemia-together-2026a10007ks?page=1&src=mkmcmr_driv_stan_mscpedu_260418-OUS-HONC-navigating-myelofibrosis-associated-anemia-together-2026a10007ks-cta&uac=148436CN

Safer Stroke Prevention on the Horizon? What the New Factor XIa Inhibitor Data Reveal Authors: Eva A. Mistry, MBBS, MSCI, FAHA; Yi Dong, MD; Xin Cheng, MD, PhD; Mike Sharma, MD, MSc, FRCPC; Ashkan Shoamanesh, MD, PhD

https://www.medscape.org/viewarticle/safer-stroke-prevention-horizon-what-new-factor-xia-2026a10004zj?page=1&uac=148436CN&src=mkmcmr_driv_il_mscpedu_260418-12174275_ES_HONC#transcript-download-es

Dissecting the Evidence: Interpreting Recent Clinical Trial Data for Radiopharmaceutical-Based Combinations in Metastatic Castration-Resistant Prostate Cancer Authors: Bertrand Tombal, MD, PhD; Alicia K. Morgans, MD, MPH, FASCO

https://www.medscape.org/viewarticle/dissecting-evidence-interpreting-recent-clinical-trial-data-2026a10009un?page=1&src=mkmcmr_driv_stan_mscpedu_260418-OUS-HONC-dissecting-evidence-interpreting-recent-clinical-trial-data-2026a10009un-cta&uac=148436CN

One Size Fits None: Patient Journeys in HR+/HER2- Metastatic Breast Cancer With CDK4/6 Inhibitors

One Size Fits None: Patient Journeys in HR+/HER2- Metastatic Breast Cancer With CDK4/6 Inhibitors Hybrid Event WEDNESDAY, 6 MAY 2026 I 11:00 - 12:00 CEST I 60 MIN Hamburg Hall, Messe Berlin, Berlin, Germany This symposium offers an in-depth review of clinical cases with comprehensive discussion from our panel of renowned international experts, Drs Thill, Cottu, and Mahtani. The programme, focusing on treatment with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer, is designed to be engaging with individualisation of care at its core. The audience will also have the opportunity to submit questions and engage with the panel directly. Join this symposium to gain practical insights and learn from the experience of leading specialists in the field. Please note, you will need to be a registered attendee of the ESMO Breast Cancer Annual Conference in order to participate.

New study highlights fructose’s unique role in metabolic disease

https://www.news-medical.net/news/20260417/New-study-highlights-fructosee28099s-unique-role-in-metabolic-disease.aspx A new report, published today in Nature Metabolism, is shedding light on the distinct and underappreciated role of fructose in driving disease, separate from its role as a simple source of calories.

Key gene variants tied to developmental dysplasia of the hip and osteoarthritis

https://www.news-medical.net/news/20260417/Key-gene-variants-tied-to-developmental-dysplasia-of-the-hip-and-osteoarthritis.aspx Developmental dysplasia of the hip (DDH) is a polygenetic disorder that increases the risk of hip osteoarthritis. A new multiethnic study finds that variations in three genes related to collagen and bone formation are linked to DDH. Other downstream genes are also linked to hip osteoarthritis. These findings point to possible mechanisms behind DDH and potential targets for new therapies against hip osteoarthritis.

Transdermal therapy restores anti-tumor immunity in bladder cancer models Preclinical data show a first-in-class transdermal bicarbonate therapy increases tumor pH, reactivates T cells and slows bladder tumor growth in mice.

https://www.drugdiscoverynews.com/transdermal-therapy-restores-anti-tumor-immunity-in-bladder-cancer-models-17130 Extracellular acidity is a common feature of many solid tumors, similar to hypoxia. Increased metabolic rates, higher glycolysis and inadequate vasculature all contribute to the accumulation of acid in the tumor microenvironment (TME). This aspect is also one of their most effective defenses.

Weekly Rundown: Research finds no increased autism risk from Tylenol during pregnancy New hair loss treatments, company acquisitions, artificial neurons, and more led the news this week.

https://www.drugdiscoverynews.com/weekly-rundown-research-finds-no-increased-autism-risk-from-tylenol-during-pregnancy-17129 Research finds no increased autism risk from acetaminophen during pregnancy Taking acetaminophen (Tylenol) during pregnancy does not increase the risk of autism spectrum disorder in children, according to a large population-based study from Denmark published in JAMA Pediatrics. Researchers analyzed more than 1.5 million births between 1997 and 2022 using national health registry data, including over 31,000 children exposed to acetaminophen in utero, and found autism rates of 1.8 percent among exposed children compared with three percent among those not exposed. This evidence aligns with a previous study in Sweden, published in 2024, which showed that initial signals of a small association between prenatal acetaminophen use and neurodevelopmental conditions disappeared once researchers accounted for shared familial factors using sibling-controlled analyses.

HER2-Mutated NSCLC: Are Your Clinical Decisions on Target? Authors: Nicolas Girard, MD, PhD

https://www.medscape.org/viewarticle/her2-mutated-nsclc-are-your-clinical-decisions-target-2026a10000gu?page=1&src=mkmcmr_driv_stan_mscpedu_260416-OUS-HONC-her2-mutated-nsclc-are-your-clinical-decisions-target-2026a10000gu-cta&uac=148436CN

“I never let breast cancer disable me.” April 15, 2026

https://news.va.gov/146174/i-never-let-breast-cancer-disable-me/ Navy Veteran diagnosed at 31 speaks candidly Heather Elliott was 31 years old when she was diagnosed with breast cancer, nearly three decades younger than the average age of diagnosis in the United States. Genetic testing showed no hereditary link, and with no family history to explain it, Elliott sought answers elsewhere. Years later, the possibility that toxic exposures during her deployment to the Gulf region may have played a role was considered. Finally, under the PACT Act, her breast cancer became recognized as service connected.

Knowledge is power: Free online mental health courses

https://news.va.gov/146130/knowledge-power-free-mental-health-courses/ Self-paced mental health tools Veterans can use anytime Are you a Veteran facing common challenges like managing anger, insomnia or substance use? Discover VeteranTraining.va.gov, VA’s award-winning online mental health resource designed just for you.

2025 Winter Conference Update: Novel and Emerging Treatment Strategies for Breast Cancer Authors: François-Clément Bidard, MD, PhD; Mothaffar F. Rimawi, MD, FACP; Nadia Harbeck, MD, PhD

https://www.medscape.org/viewarticle/winter-conference-update-novel-and-emerging-treatment-2026a100030r?page=1&src=mkmcmr_driv_stan_mscpedu_260417-OUS-HONC-winter-conference-update-novel-and-emerging-treatment-2026a100030r-cta&uac=148436CN

Physical Activity and Community: Getting the Best of Both Worlds

https://www.hiv.gov/blog/physical-activity-and-community-getting-the-best-of-both-worlds?utm_source=newsletter&utm_medium=email&utm_campaign=blog&j=2953580&sfmc_sub=6992026&l=6498_HTML&u=73356258&mid=100006181&jb=0

Pancreatic Cancer: Clinical Trials Drive Therapy Towards Precision Medicine Dr David Cheng and Professor Naureen Starling assess ESMO guidance on pancreatic cancer, and discuss recent advances that aim to move therapy options beyond surgical resection Dr David Cheng, Professor Naureen Starling January 22, 2025

https://reference.medscape.com/cc1/p10/pancreatic-cancer-clinical-trials-drive-therapy-towards-2025a10000zk?ecd=WNL_drugguide_260417_MSCPREF_onc_etid8270090&uac=148436CN&impID=8270090

Top Tips: Metastatic Breast Cancer Dr Fharat Raja provides 10 top tips for oncologists on metastatic breast cancer, encompassing the latest UK, European, and US guidance Dr Fharat Raja May 29, 2025

https://reference.medscape.com/cc1/p10/top-tips-metastatic-breast-cancer-2025a1000dc0?ecd=WNL_drugguide_260417_MSCPREF_onc_etid8270090&uac=148436CN&impID=8270090

Diagnosis and Management of Sinonasal Malignancies Source: Resteghini C, Baujat B, Bossi P et al; Medically Reviewed by Professor Vlad Sandulache September 10, 2025

https://reference.medscape.com/cc2/p10/guideline-essentials-esmo-recommendations-diagnosis-and-2025a1000cup?ecd=WNL_drugguide_260417_MSCPREF_onc_etid8270090&uac=148436CN&impID=8270090

Cancer Immunotherapy: Urothelial Cancer Source: Society for Immunotherapy of Cancer March 21, 2025

https://reference.medscape.com/cc2/p10/sitc-urothelial-cancer-immunotherapy-2025a10000i6?ecd=WNL_drugguide_260417_MSCPREF_onc_etid8270090&uac=148436CN&impID=8270090

Immunotherapy for Lung Cancer and Mesothelioma Source: Society for Immunotherapy of Cancer March 31, 2026

https://reference.medscape.com/cc2/p10/sitc-guideline-immunotherapy-lung-cancer-and-mesothelioma-2026a10009o2?ecd=WNL_drugguide_260417_MSCPREF_onc_etid8270090&uac=148436CN&impID=8270090

Neuroendocrine Neoplasms Source: European Society for Medical Oncology March 13, 2026

https://reference.medscape.com/cc2/p10/esmo-guideline-neuroendocrine-neoplasms-2026a10007ak?ecd=WNL_drugguide_260417_MSCPREF_onc_etid8270090&uac=148436CN&impID=8270090

Chronic Lymphocytic Leukemia (CLL): Review of Combination Approaches Authors: Jonathon Cohen, MD, MS; Matthew S. Davids, MD, MMSc

https://www.medscape.org/viewarticle/chronic-lymphocytic-leukemia-cll-review-combination-2026a10004ku?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260417-OUS-HONC-chronic-lymphocytic-leukemia-cll-review-combination-2026a10004ku-cta

Small Steps and Giant Leaps: Charting a Course for Cardiovascular Disease Prevention

https://www.familyheartsummit.org/event/743c2275-3b7b-442d-adcc-c5d8b9040207/summary Join us for the 12th Annual Family Heart Global Summit Artemis II made its splashdown off the coast of San Diego, and that’s exactly where we’re landing next. We’re bringing that same spirit of exploration to this year’s Family Heart Global Summit, Small Steps and Giant Leaps: Charting a Course for Cardiovascular Disease Prevention, and we are honored to be joined by special guest and keynote speaker astronaut Robert L. Curbeam, Jr. Join leaders across cardiology, genetics, and AI in medicine as we work toward a thoughtful and effective framework to expand prevention for all, with a special focus on inherited lipid disorders including familial hypercholesterolemia and high lipoprotein(a). Seats are filling quickly, we hope you’ll join us.

Beyond PSMA: Preparing Your Practice for the Next Wave of Prostate Cancer Biomarkers Authors: Karim Fizazi, MD, PhD; Bertrand Tombal, MD, PhD; Alberto Briganti, MD, PhD

https://www.medscape.org/viewarticle/beyond-psma-preparing-your-practice-next-wave-prostate-2026a10006ql?page=1&uac=148436CN&src=mkmcmr_driv_il_mscpedu_260417-12186951_ES_HONC#transcript-download-es

Navigating the HER2 Spectrum in Breast Cancer: Evolving Diagnostic Paradigms for Clinical Excellence Authors: Sara M. Tolaney, MD, MPH; Frédérique Penault-Llorca, MD; Giuseppe Curigliano, MD, PhD

https://www.medscape.org/viewarticle/navigating-her2-spectrum-breast-cancer-evolving-diagnostic-2026a10004ea?page=1&src=mkmcmr_driv_stan_mscpedu_260417-OUS-HONC-navigating-her2-spectrum-breast-cancer-evolving-diagnostic-2026a10004ea-cta&uac=148436CN

Tenosynovial Giant Cell Tumor in Focus: Quickfire Insights From Multidisciplinary Experts Authors: Hans Gelderblom, MD, PhD; Michiel van de Sande, MD, PhD

https://www.medscape.org/viewarticle/tenosynovial-giant-cell-tumor-focus-quickfire-insights-2026a10006py?page=1&src=mkmcmr_driv_stan_mscpedu_260418-OUS-HONC-tenosynovial-giant-cell-tumor-focus-quickfire-insights-2026a10006py-cta&uac=148436CN

Obesity, GLP-1s, and metabolic care

https://www.news-medical.net/news/20260417/Obesity-GLP-1s-and-metabolic-care.aspx An interview with Professor Thomas Forst, Chief Medical Officer, hVIVO Obesity research is a rapidly developing field, and few areas have advanced faster than incretin-based medicines such as GLP-1 receptor agonists.

Smoothies vs juice: study reveals which fruit form is healthiest

https://www.news-medical.net/news/20260417/Smoothies-vs-juice-study-reveals-which-fruit-form-is-healthiest.aspx Smoothies may offer a surprising edge over juices and even whole fruit, with researchers linking them to better health markers, but lifestyle factors could be shaping the story. A study in Frontiers in Nutrition found that certain forms of fruit consumption, particularly fruit smoothies and solid fruit, are associated with better health outcomes than fruit juices.

Current and Future Oral SERD Strategies in the Management of ER-Positive/HER2-Negative MBC: Analyzing the Clinical Data Authors: Komal Jhaveri, MD, FACP, FASCO; Shaheenah Dawood, MD, MPH

https://www.medscape.org/viewarticle/current-and-future-oral-serd-strategies-management-er-2026a100022b?page=1&src=mkmcmr_driv_stan_mscpedu_260416-OUS-HONC-current-and-future-oral-serd-strategies-management-er-2026a100022b-cta&uac=148436CN

Ongoing Perspectives in HER2-Mutated Advanced NSCLC: An Expert Viewpoint on the Latest Data Authors: Helena Yu, MD

https://www.medscape.org/viewarticle/ongoing-perspectives-her2-mutated-advanced-nsclc-expert-2026a10001va?page=1&src=mkmcmr_driv_stan_mscpedu_260417-OUS-HONC-ongoing-perspectives-her2-mutated-advanced-nsclc-expert-2026a10001va-cta&uac=148436CN

The importance of safeguarding hydration for healthy ageing The Lancet Healthy Longevity ++... ++

The importance of safeguarding hydration for healthy ageing The Lancet Healthy Longevity https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(26)00030-9/fulltext?dgcid=raven_jbs_etoc_email Mar 2026 Volume 7Number 3 https://www.thelancet.com/journals/lanhl/issue/vol7no3/PIIS2666-7568(26)X2003-7 Risk factors for early-onset and late-onset dementia: a prospective cohort study Katherine Giorgio, MSa ∙ John J Stephen, MPHb ∙ Maxwell Mansolf, PhDc ∙ Elizabeth A Peterson, MPHb ∙ Prof Alden L Gross, PhDd ∙ Emily M Briceño, PhDe ∙ et al. https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(26)00015-2/fulltext?dgcid=raven_jbs_etoc_feature_lanhl The role of frailty and comorbidities in severe infections and the risk of dementia: a prospective, multicohort, observational study Pyry N Sipilä, MDa pyry.sipila@helsinki.fi ∙ Jaana Pentti, MSca,c ∙ Philipp Frank, PhDd ∙ Michael R Duggan, PhDe ∙ Keenan A Walker, PhDe ∙ Prof Timo E Strandberg, MDb,f,g ∙ et al. https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(26)00010-3/fulltext?dgcid=raven_jbs_etoc_feature_lanhl

Most Read Cancer Science & Oncogenesis +...

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_260417

HER2-Mutated NSCLC: Are Your Clinical Decisions on Target? Authors: Nicolas Girard, MD, PhD

https://www.medscape.org/viewarticle/her2-mutated-nsclc-are-your-clinical-decisions-target-2026a10000gu?page=1&src=mkmcmr_driv_stan_mscpedu_260413-OUS-HONC-her2-mutated-nsclc-are-your-clinical-decisions-target-2026a10000gu-cta&uac=148436CN

World Autism Awareness Day: autism and metabolic health The Lancet Diabetes & Endocrinology + +... +

World Autism Awareness Day: autism and metabolic health The Lancet Diabetes & Endocrinology https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00079-3/fulltext?dgcid=raven_jbs_etoc_email May 2026 Volume 14Number 5p363-436, e8 https://www.thelancet.com/journals/landia/issue/vol14no5/PIIS2213-8587(26)X2003-4 Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study Patrik Smidtslund, MDa,b,e ∙ Valma Harjutsalo, PhDa,b,e ∙ Ville Thorn, MDc ∙ Fanny Jansson Sigfrids, DMSca,b,e ∙ Per-Henrik Groop, DMSca,b,e,f,g ∙ Lena M Thorn, DMSca,b,d,e lena.thorn@helsinki.fi ∙ et al. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00368-7/abstract?dgcid=raven_jbs_etoc_feature_landia

Patient Partnership Webinar - Lupus100 and beyond by Lupus Europe and ERN RECONNET

12th EAN Congress - 12th Congress of the European Academy of Neurology - Geneva 2026

https://www.ean.org/ 12th EAN Congress Our Associate Partner, the European Academy of Neurology (EAN), will host its 12th Congress in Geneva from 27–30 June 2026, focusing on how technology and artificial intelligence are transforming neurology. Bringing together clinicians, researchers and experts, the congress provides a space to exchange knowledge, discuss challenges, and strengthen connections across the neurological and rare disease communities. https://www.ean.org/congress2026

SMA FINLAND

https://smafinland.fi/ From possibility to reality: rethinking pregnancy in SMA In this article, Lassi Murto from EURORDIS member organisation SMA Finland ry reflects on how advances in treatment are reshaping what is possible for women living with spinal muscular atrophy (SMA), including the prospect of pregnancy and parenthood. Drawing on lived experience within the community, the piece highlights a key shift: while possibilities are expanding, support systems have not always kept pace. It calls for more coordinated care, access to expertise, and informed guidance to ensure women with SMA can make safe and supported choices https://www.eurordis.org/from-possibility-to-reality-rethinking-pregnancy-in-sma/

Learn with the Open Academy

https://openacademy.eurordis.org/ Ethics in clinical trials Want to learn more about medical research ethics? The EURORDIS Open Academy offers a course on the history and necessity of the guidelines and principles followed to ensure participants' rights and well-being are protected in any clinical setting. Enrol now!

Health Data Ethics & Regulatory Frameworks in Rare Disease Research

Health Data Ethics & Regulatory Frameworks in Rare Disease Research Discover the role of health data in rare disease research, exploring the ethics and regulatory frameworks governing data use. https://www.futurelearn.com/courses/health-data-ethics-and-regulatory-frameworks-in-rare-disease-research Health data ethics Interested in health data's role in rare disease research? EURORDIS and partners within the European Joint Programme on Rare Diseases have developed the FutureLearn course Health Data Ethics and Regulatory Frameworks in Rare Disease Research. Join guided discussions, engage with experts (including EURORDIS’ Head of Research Policy, Roseline Favresse) and explore key topics, including data ethics, privacy, and regulatory frameworks.

Challenges and opportunities for the use of telehealth in rare disease diagnosis, treatment, research, and education: key opinion leader interviews by the IRDiRC telehealth task force

https://journals.sagepub.com/doi/10.1177/26330040261427023 This article published by the International Rare Diseases Research Consortium (IRDiRC),of which EURORDIS is a member, explores the potential of telehealth to transform care, research and training in rare diseases. Drawing on insights from international experts, it highlights how telehealth can improve access to specialist expertise and support more inclusive research, while also outlining key challenges related to infrastructure, regulation, and equitable access across healthcare systems. https://irdirc.org/

Open Access Government April 2026 April 7, 2026

Open Access Government April 2026 April 7, 2026 We’re pleased to present our April 2026 publication, marking the 50th edition of Open Access Government. As environmental and political concerns take centre stage, we strive to offer diverse insights from experts in healthcare, research, and policy https://www.openaccessgovernment.org/publication/open-access-government-april-2026/206289/ In a recent article published in the April edition of Open Access Government, François Houÿez, EURORDIS’ Director of Treatment Information and Access, explores the growing role of artificial intelligence in healthcare and its implications for people living with rare diseases. Francois highlights both the potential of AI to support diagnosis and treatment, and the challenges it raises around data limitations, human oversight, and the need for meaningful patient engagement and trust.

10 Minutes With Rhiannon Walls

https://www.eurordis.org/10-minutes-with-rhiannon-walls/ GIF of Rhiannon Walls and Allison Watson having a conversation, against a backdrop of plants. 10 Minutes With... Catch up on the latest episode of our 10 Minutes With series, hosted by EURORDIS’ Rhiannon Walls. In this conversation, Allison Watson, CEO of Ring20 Research & Support UK and Volunteer Awardee at the 2026 Black Pearl Awards, shares her journey from everyday family life into advocacy for ultra-rare diseases such as Ring Chromosome 20 syndrome. Together, they explore challenges in diagnosis, limited research and treatment options, and the vital role of patient-led communities and peer support.

ERN affiliated partners

https://health.ec.europa.eu/consultations/ern-call-2026_en#details On 13 April, the European Commission launched a call for affiliated partners to the European Reference Networks (ERNs), aiming to improve geographical coverage of ERN expertise, strengthen their integration into national healthcare systems and support cross-border knowledge exchange and clinical collaboration. Eligible countries include Bulgaria, Cyprus, Croatia, Czechia, Estonia, Greece, Ireland, Latvia, Norway, Poland, Portugal, Romania, Slovenia and Slovakia.

EURORDIS - Rare Diseases Europe (EURORDIS) : Listening to Experiences: The Impact of Patient Involvement in ATMP Clinical Trial Design

https://www.join4atmp.eu/partners/eurordis On April 14, we held our first Join4ATMP webinar as part of a new series, exploring how patient involvement can shape better clinical trials for Advanced Therapy Medicinal Products (ATMPs) including gene and cell therapies. The first session brought together patients, researchers and developers to share real-world insights and highlight practical ways to make trials more patient-centred. Listening to Experiences: The Impact of Patient Involvement in ATMP Clinical Trial Design

European Parliament Event on Rare Diseases: Placing Patients at the Centre of a Future European Framework April 2026

European Parliament Event on Rare Diseases: Placing Patients at the Centre of a Future European Framework April 2026 Date: 23 April 2026 📍 Location: European Parliament, Brussels and Online ⏰ Time: 09:00-11:00 CEST https://www.eurordis.org/european-parliament-event-on-rare-diseases/ European Parliament EURORDIS and MEP Nicolás González Casares are organising a European Parliament event to bring patient voices directly into discussions on a future EU framework for rare diseases. As the Parliament advances work on an EU Action Plan, this event will provide a dedicated space for patient organisations, advocates and healthcare professionals to exchange perspectives and help ensure that future policy reflects patients’ lived experiences.

Breaking the bottlenecks: How a more globally competitive Europe should get more and better treatments to patients April 2026

Breaking the bottlenecks: How a more globally competitive Europe should get more and better treatments to patients April 2026 Rare diseases are individually uncommon but collectively touch the lives of around 30 million people across Europe, and more than 300 million worldwide. Yet around 95% of rare conditions still lack an authorised treatment, and even those with one face a series of bottlenecks: regulatory pathways that can take years, evidence standards that are difficult to meet with small patient populations, and reimbursement negotiations that vary dramatically by country. https://www.eurordis.org/breaking-the-bottlenecks-more-treatments-for-patients/

Patient Stories: How Palliative Care Helps with Anxiety, Pain, and More

https://getpalliativecare.org/patient-stories-how-palliative-care-helps-with-anxiety-pain-and-more/?utm_source=Get+Palliative+Care&utm_campaign=8c570c48c4-GPC+-+Sheralin+Patient+Story+%2F+04.15.26&utm_medium=email&utm_term=0_4ef32a103e-8c570c48c4-378264050 Sometimes, reading about palliative care isn’t enough, hearing someone’s story brings its impact to life. Sheralin cares for her mother, who has young-onset Alzheimer’s disease. Once a strong, hardworking single mother, her mom’s diagnosis brought unexpected challenges. Palliative care offered the support she needed. The team helped coordinate additional care for her mother while also supporting Sheralin’s own stress, depression, and anxiety, giving her tools to navigate the emotional realities of caregiving.

Immunotherapy for Non-Muscle-Invasive Bladder Cancer: Expert Takeaways From the Latest Updates Authors: Bernadett Szabados, MD; Maria De Santis, MD; Neal D. Shore, MD, FACS

https://www.medscape.org/viewarticle/immunotherapy-non-muscle-invasive-bladder-cancer-expert-2026a10005af?page=1&src=mkmcmr_driv_stan_mscpedu_260415-OUS-HONC-immunotherapy-non-muscle-invasive-bladder-cancer-expert-2026a10005af-cta&uac=148436CN

Targeting chromosomal chaos Accent Therapeutics advances a KIF18A inhibitor, leveraging genomic instability to create druggable dependencies.

https://www.drugdiscoverynews.com/targeting-chromosomal-chaos-17128 At the 2026 international conference of the Society for Laboratory Automation and Screening (SLAS), Serena Silver, Chief Scientific Officer of Accent Therapeutics, laid out a precision oncology strategy built around a structural feature of cancer genomes rather than a single mutated gene.

Bicillin® L-A Shortage

https://www.hiv.gov/blog/bicillin-l-a-shortage?utm_source=newsletter&utm_medium=email&utm_campaign=blog&j=2951969&sfmc_sub=6992026&l=6498_HTML&u=73303456&mid=100006181&jb=0 CDC has learned that the U.S. Food and Drug Administration (FDA) is allowing the temporary importation of Lentocilin© due to the ongoing limited availability and extended recovery of Bicillin® L-A (Penicillin G Benzathine Injectable Suspension, produced by King Pharmaceuticals LLC, a subsidiary of Pfizer). The National Network of STD Prevention Training Centers has posted information for health care providers on the administration of Lentocilin©. https://courses.nnptc.org/resource_detail.html?id=2718

Keys to Diagnosing 'Broken Heart Syndrome' (Takotsubo Cardiomyopathy) Mark P. Brady, PA-C; Yasmine S. Ali, MD, MSci, FACC, FACCP April 09, 2026

https://reference.medscape.com/p11/keys-diagnosing-broken-heart-syndrome-takotsubo-2026a10009hh?ecd=mkm_ret_260416_mscpmrk-OUS_DisReferences_etid8256303&uac=148436CN&impID=8256303 Takotsubo Cardiomyopathy (TCM) TCM, first described in 1990 by Sato et al,[1,2,3] is a transient cardiac syndrome that typically involves left ventricular (LV) apical akinesis and basal hypercontraction; it may symptomatically mimic acute coronary syndrome (ACS).[1,2,4]

Putting placebo effects in a new light The Lancet Psychiatry ++... + +

Putting placebo effects in a new light The Lancet Psychiatry https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00096-9/fulltext?dgcid=raven_jbs_etoc_email May 2026 Volume 13Number 5p365-444, e8 https://www.thelancet.com/journals/lanpsy/issue/vol13no5/PIIS2215-0366(26)X2003-X Harnessing placebo effects and mitigating nocebo effects: implications for clinical practice in psychiatry and medicine Matthew J Burke, MDa,b,c,d matt.burke@utoronto.ca ∙ Dasha A Sandra, MSce ∙ Marta Peciña, MDg ∙ Jay A Olson, PhDf ∙ Adriano Mollica, MDa,c ∙ Matthew Butler, MDh ∙ et al. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(25)00340-2/abstract?dgcid=raven_jbs_etoc_feature_lanpsy Confirmatory efficacy and safety trial of magnetic seizure therapy versus right unilateral ultra-brief electroconvulsive therapy in depression (CREST–MST): a randomised, double-blind, non-inferiority trial in Canada and the USA Prof Daniel M Blumberger, MDa,b daniel.blumberger@camh.ca ∙ Prof Shawn M McClintock, PhDe,f ∙ Kevin E Thorpe, MMathc,g ∙ Prof Carol A Tamminga, MDe ∙ Karen Foleyd,h ∙ Prof Mustafa M Husain, MDe ∙ et al. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00060-X/fulltext?dgcid=raven_jbs_etoc_feature_lanpsy

Autism spectrum disorder: strengthening screening for optimal outcomes The Lancet Regional Health – Southeast Asia + + +...

Low-dose nivolumab with neoadjuvant chemotherapy and oral metronomic therapy in borderline resectable oral cavity squamous cell carcinoma: a phase II trial Praveen Kumar Marimuthua Drmpk91@gmail.com ∙ Chitra Renukaradhyab chitraardhya@gmail.com ∙ Shalini Sahuc sahushalini07@gmail.com ∙ Ajoy Oommen Johna ajoyoommenjohn@gmail.com ∙ Amit Jiwan Tirkeyd jiwan@cmcvellore.ac.in ∙ Balu Krishna Sasidharane balunair@cmcvellore.ac.in ∙ et al. https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(26)00028-4/fulltext?dgcid=raven_jbs_etoc_feature_lansea Autism spectrum disorder: strengthening screening for optimal outcomes The Lancet Regional Health – Southeast Asia https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(26)00056-9/fulltext?dgcid=raven_jbs_etoc_email Apr 2026 Volume 47 https://www.thelancet.com/journals/lansea/issue/vol47nonull/PIIS2772-3682(26)X2002-9

Incidental PSA Elevation in a 69-Year-Old Former Smoker with Hypertension Abdul Baseet Arham, MBBS; Valentina Marulanda-Corzo, MD; Scott T. Tagawa, MD, MS April 14, 2026

https://reference.medscape.com/viewarticle/incidental-psa-elevation-69-year-old-former-smoker-2026a1000al6?_gl=1*mxkwiq*_gcl_au*MTAzMjcwMzM1OC4xNzcyODkzMjkyLjE1Nzc3NzY2MjguMTc3NjM0Njc1OS4xNzc2MzQ4Nzgy

A Plea for Laterality in Cancer Research and Medicine David Kerr, MD, DSc April 16, 2026

https://www.medscape.com/viewarticle/plea-laterality-cancer-research-and-medicine-2026a1000aqx I first noticed this when I was the president of the European Society for Medical Oncology. I worked with my colleagues, then the presidents of the European Societies of Cardiology, Respiratory Medicine, and Diabetes, to come together as a chronic disease alliance so that we could lobby the United Nations on behalf of noncommunicable diseases. At that political level, it worked very well.

Long-Term Physical Decline After Breast Cancer Therapy Maurie Markman, MD April 14, 2026

https://www.medscape.com/viewarticle/long-term-physical-decline-after-breast-cancer-therapy-2026a1000aft Hello. I’m Dr Maurie Markman, from City of Hope. In this segment, I would like to discuss a very important paper that I think needs further conversation and also other papers to follow up. Here’s what I’m going to be talking about. The paper was entitled, “Physical Health Decline After Chemotherapy or Endocrine Therapy in Breast Cancer Survivors,” published in JAMA Network Open.

Treating Residual HER2+ Disease After Neoadjuvant TCHP Jame Abraham, MD April 15, 2026

https://www.medscape.com/viewarticle/treating-residual-her2-disease-after-neoadjuvant-tchp-2026a1000agq Recently, I saw a 45-year-old patient who presented with a palpable left breast mass. The imaging showed a 5.6-cm mass, with multiple ipsilateral axillary lymph nodes present. The biopsy showed a poorly differentiated tumor, invasive ductal cancer, estrogen-receptor (ER)/progesterone-receptor (PR) negative, HER2-positive, 3+ with immunohistochemistry, and the biopsy of the axillary lymph nodes were also positive.

Dendritic Cell Strategies May Reduce Cancer Recurrence Risk Carole Stavart Medscape Europe April 16, 2026

https://www.medscape.com/viewarticle/dendritic-cell-strategies-may-reduce-cancer-recurrence-risk-2026a1000bxp Damya Laoui, PhD, a bioengineer and immunologist at the Brussels Center for Immunology of the Department of Bioengineering Sciences in Brussels, Belgium, and the Flemish Institute of Biotechnology in Ghent, Belgium, is investigating how dendritic cells within tumors may be used to reduce the risk for cancer recurrence.